https://www.pharmatlas.org/ 2026-04-16T17:08:35+00:00 https://www.pharmatlas.org/ https://www.pharmatlas.org/lib/exe/fetch.php?media=logo.png text/html 2026-02-13T00:19:30+00:00 Anonymous (anonymous@undisclosed.example.com) https://www.pharmatlas.org/doku.php?id=endocrine:glp1:dulaglutide&rev=1770941970&do=diff Dulaglutide Dulaglutide is a long-acting, once-weekly GLP-1 receptor agonist used for Type 2 Diabetes and cardiovascular risk reduction. Brand: * Trulicity → GLP-1 Receptor Agonists Overview Mechanism of Action Dulaglutide activates the GLP-1 receptor. Effects: * Increases glucose-dependent insulin secretion text/html 2026-02-13T00:20:36+00:00 Anonymous (anonymous@undisclosed.example.com) https://www.pharmatlas.org/doku.php?id=endocrine:glp1:exenatide&rev=1770942036&do=diff Exenatide Exenatide was the first FDA-approved GLP-1 receptor agonist (2005) for Type 2 Diabetes. Brand names: * Byetta (twice daily) * Bydureon (once weekly extended-release) → GLP-1 Receptor Agonists Overview Mechanism of Action Exenatide activates the GLP-1 receptor. text/html 2026-02-13T00:20:04+00:00 Anonymous (anonymous@undisclosed.example.com) https://www.pharmatlas.org/doku.php?id=endocrine:glp1:liraglutide&rev=1770942004&do=diff Liraglutide Liraglutide is a once-daily GLP-1 receptor agonist used for Type 2 Diabetes, obesity, and cardiovascular risk reduction. Brand names: * Victoza (Type 2 Diabetes) * Saxenda (Obesity) → GLP-1 Receptor Agonists Overview Mechanism of Action Liraglutide activates the GLP-1 receptor. text/html 2026-02-13T00:17:01+00:00 Anonymous (anonymous@undisclosed.example.com) https://www.pharmatlas.org/doku.php?id=endocrine:glp1:semaglutide&rev=1770941821&do=diff Semaglutide Semaglutide is a long-acting GLP-1 receptor agonist used for Type 2 Diabetes, obesity, and cardiovascular risk reduction. Brand names: * • Ozempic (Type 2 Diabetes) * • Wegovy (Obesity) * • Rybelsus (Oral formulation) → text/html 2026-02-13T00:14:18+00:00 Anonymous (anonymous@undisclosed.example.com) https://www.pharmatlas.org/doku.php?id=endocrine:glp1:start&rev=1770941658&do=diff GLP-1 Receptor Agonists GLP-1 receptor agonists are incretin-based therapies that enhance glucose-dependent insulin secretion and promote weight loss. They are foundational agents in: • Type 2 Diabetes Mellitus • Obesity • Atherosclerotic Cardiovascular Disease (ASCVD)